Zacks.com Spotlights Phibro Animal Health, Astronics, CommScope, and Heritage Insurance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy PAHC?
Source: NASDAQ.COM
Stocks Near 52-Week Highs: The article highlights four stocks—Phibro Animal Health, Astronics, CommScope, and Heritage Insurance—that are trading near their 52-week highs and are expected to continue their upward momentum, despite concerns about potential overvaluation.
Phibro Animal Health: The company is experiencing strong growth in its Animal Health business, bolstered by strategic acquisitions and investments in vaccine manufacturing, leading to a positive earnings outlook.
Astronics: Benefiting from increased global demand in defense and commercial aerospace, Astronics has expanded its product portfolio through acquisitions, which is expected to enhance its sales and earnings in the near term.
CommScope and Heritage Insurance: CommScope is innovating in 5G technology solutions, while Heritage Insurance focuses on optimizing its insurance portfolio and investing in technology to manage risks effectively, both showing promising earnings growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 51.850
Low
45.00
Averages
47.50
High
50.00
Current: 51.850
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
- Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
- Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
- Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
- Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
See More
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
- Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
- Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
- Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
- Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares for $3.74 Million
- Executive Sell-Off: Jack Bendheim, President and CEO of Phibro Animal Health, sold 72,198 shares through an indirect entity, BFI Co. LLC, between February 10 and 11, 2026, for approximately $3.74 million at an average price of $51.77 per share, indicating a cautious stance on the company's future despite strong past performance.
- Stable Holdings: Despite the significant indirect sale, Bendheim's direct holdings remain unchanged at 16,840 shares, reflecting his confidence in the company's long-term prospects and a strategy that is not swayed by short-term market fluctuations.
- Positive Financial Performance: In its recent Q2 earnings report for fiscal year 2026, Phibro reported year-over-year growth in revenue, net income, and earnings per share, highlighting strong demand for its animal nutrition products and vaccines, which bolsters investor confidence in the company.
- Optimistic Market Outlook: With ongoing threats from diseases like avian influenza, Phibro's medicated feed additive portfolio is expected to continue growing, especially after acquiring over 37 product lines in late 2024, further solidifying its market position and addressing critical needs in the agricultural sector.
See More
Phibro Animal Health to Participate in 2026 Summit
- Executive Participation: Phibro Animal Health Corporation will participate in the Bank of America 2026 Virtual Animal Health Summit on February 26, 2026, where CFO Glenn David, COO Larry Miller, and CEO designate Daniel Bendheim will address financial analysts and investors, likely enhancing the company's visibility in the industry.
- Live and Archived Access: The live audio presentation will be available on Phibro's Investor Relations website, with a replay archived for later access, ensuring that investors unable to attend in real-time can still obtain relevant information, thereby increasing transparency and investor trust.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, showcasing its expertise and market position in the animal health sector.
- Information Access Channels: The company offers multiple channels for investors to access information, including filings with the Securities and Exchange Commission and its website, ensuring that investors can stay updated on the latest developments and financial status, further enhancing communication with stakeholders.
See More
Amazon's Huge Capital Spending Leads to Futures Losses and Bitcoin Bounce
- Market Volatility: Futures markets pared losses after the stock market broke key levels, indicating investor concerns about future economic prospects, which could lead to short-term market instability.
- Amazon's Capital Spending: Amazon's stock fell due to significant capital expenditures, reflecting the company's aggressive strategy in expansion and infrastructure investment, which may impact its short-term profitability.
- Bitcoin Bounce: Despite overall market pressure, Bitcoin saw a slight bounce, indicating a demand for digital assets as a safe haven in uncertain market conditions, potentially attracting more investor interest.
- Investor Sentiment: The market's strong reaction to Amazon's spending may lead investors to reassess the risk and return of tech stocks, influencing overall investment strategies.
See More
Stock Market Plummets Amid Amazon Earnings Miss
- Market Decline: The stock market experienced a significant sell-off on Thursday, with major indices declining broadly, reflecting investor concerns about the economic outlook amid high inflation and rising interest rates, which have dampened market confidence.
- Bitcoin Crash: Bitcoin prices fell sharply, driven by a bearish market sentiment as investors rushed to sell off crypto assets, likely due to concerns over increased regulation in the crypto market and a general rise in risk aversion.
- Amazon Earnings Miss: Amazon's stock price dropped following its earnings report, primarily due to concerns over its massive capital spending plans, which raised investor apprehensions about future profitability, highlighting the tension between expansion and earnings.
- Capital Expenditure Impact: While Amazon's capital expenditure plans aim to drive long-term growth, they may negatively affect cash flow and shareholder returns in the short term, leading to lowered market expectations for its future performance.
See More
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
- Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
- Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
- Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
- Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
See More
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
- Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
- Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
- Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
- Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares for $3.74 Million
- Executive Sell-Off: Jack Bendheim, President and CEO of Phibro Animal Health, sold 72,198 shares through an indirect entity, BFI Co. LLC, between February 10 and 11, 2026, for approximately $3.74 million at an average price of $51.77 per share, indicating a cautious stance on the company's future despite strong past performance.
- Stable Holdings: Despite the significant indirect sale, Bendheim's direct holdings remain unchanged at 16,840 shares, reflecting his confidence in the company's long-term prospects and a strategy that is not swayed by short-term market fluctuations.
- Positive Financial Performance: In its recent Q2 earnings report for fiscal year 2026, Phibro reported year-over-year growth in revenue, net income, and earnings per share, highlighting strong demand for its animal nutrition products and vaccines, which bolsters investor confidence in the company.
- Optimistic Market Outlook: With ongoing threats from diseases like avian influenza, Phibro's medicated feed additive portfolio is expected to continue growing, especially after acquiring over 37 product lines in late 2024, further solidifying its market position and addressing critical needs in the agricultural sector.
See More
Phibro Animal Health to Participate in 2026 Summit
- Executive Participation: Phibro Animal Health Corporation will participate in the Bank of America 2026 Virtual Animal Health Summit on February 26, 2026, where CFO Glenn David, COO Larry Miller, and CEO designate Daniel Bendheim will address financial analysts and investors, likely enhancing the company's visibility in the industry.
- Live and Archived Access: The live audio presentation will be available on Phibro's Investor Relations website, with a replay archived for later access, ensuring that investors unable to attend in real-time can still obtain relevant information, thereby increasing transparency and investor trust.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, showcasing its expertise and market position in the animal health sector.
- Information Access Channels: The company offers multiple channels for investors to access information, including filings with the Securities and Exchange Commission and its website, ensuring that investors can stay updated on the latest developments and financial status, further enhancing communication with stakeholders.
See More
Amazon's Huge Capital Spending Leads to Futures Losses and Bitcoin Bounce
- Market Volatility: Futures markets pared losses after the stock market broke key levels, indicating investor concerns about future economic prospects, which could lead to short-term market instability.
- Amazon's Capital Spending: Amazon's stock fell due to significant capital expenditures, reflecting the company's aggressive strategy in expansion and infrastructure investment, which may impact its short-term profitability.
- Bitcoin Bounce: Despite overall market pressure, Bitcoin saw a slight bounce, indicating a demand for digital assets as a safe haven in uncertain market conditions, potentially attracting more investor interest.
- Investor Sentiment: The market's strong reaction to Amazon's spending may lead investors to reassess the risk and return of tech stocks, influencing overall investment strategies.
See More
Stock Market Plummets Amid Amazon Earnings Miss
- Market Decline: The stock market experienced a significant sell-off on Thursday, with major indices declining broadly, reflecting investor concerns about the economic outlook amid high inflation and rising interest rates, which have dampened market confidence.
- Bitcoin Crash: Bitcoin prices fell sharply, driven by a bearish market sentiment as investors rushed to sell off crypto assets, likely due to concerns over increased regulation in the crypto market and a general rise in risk aversion.
- Amazon Earnings Miss: Amazon's stock price dropped following its earnings report, primarily due to concerns over its massive capital spending plans, which raised investor apprehensions about future profitability, highlighting the tension between expansion and earnings.
- Capital Expenditure Impact: While Amazon's capital expenditure plans aim to drive long-term growth, they may negatively affect cash flow and shareholder returns in the short term, leading to lowered market expectations for its future performance.
See More
